Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Director Angie You Acquires 26,597 Shares

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) Director Angie You purchased 26,597 shares of the stock in a transaction that occurred on Friday, June 20th. The shares were purchased at an average price of $9.39 per share, with a total value of $249,745.83. Following the completion of the acquisition, the director now directly owns 26,597 shares in the company, valued at $249,745.83. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Angie You also recently made the following trade(s):

• On Monday, June 23rd, Angie You purchased 1,403 shares of Oric Pharmaceuticals stock. The shares were purchased at an average price of $9.43 per share, with a total value of $13,230.29.

Oric Pharmaceuticals Trading Up 7.4%

NASDAQ ORIC traded up $0.69 during trading on Monday, hitting $10.00. The company had a trading volume of 814,185 shares, compared to its average volume of 784,830. Oric Pharmaceuticals, Inc. has a one year low of $3.90 and a one year high of $14.67. The company has a market cap of $852.20 million, a price-to-earnings ratio of -5.35 and a beta of 1.49. The company's fifty day moving average is $6.71 and its 200-day moving average is $7.66.

Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.51) by $0.09. As a group, equities analysts anticipate that Oric Pharmaceuticals, Inc. will post -2.17 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. KLP Kapitalforvaltning AS bought a new position in shares of Oric Pharmaceuticals in the 4th quarter worth about $50,000. Arizona State Retirement System bought a new stake in Oric Pharmaceuticals during the 1st quarter valued at about $56,000. BNP Paribas Financial Markets bought a new stake in Oric Pharmaceuticals during the 4th quarter valued at about $71,000. Hsbc Holdings PLC bought a new stake in Oric Pharmaceuticals during the 1st quarter valued at about $102,000. Finally, PNC Financial Services Group Inc. increased its stake in Oric Pharmaceuticals by 22.9% during the 4th quarter. PNC Financial Services Group Inc. now owns 13,517 shares of the company's stock valued at $109,000 after purchasing an additional 2,520 shares in the last quarter. 95.05% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. JPMorgan Chase & Co. upped their price target on shares of Oric Pharmaceuticals from $21.00 to $22.00 and gave the company an "overweight" rating in a report on Wednesday, February 26th. Wedbush reissued an "outperform" rating and set a $20.00 price objective on shares of Oric Pharmaceuticals in a research report on Monday. HC Wainwright restated a "buy" rating and issued a $21.00 price objective on shares of Oric Pharmaceuticals in a report on Monday, May 5th. Cantor Fitzgerald restated an "overweight" rating on shares of Oric Pharmaceuticals in a report on Tuesday, May 6th. Finally, Oppenheimer decreased their price objective on shares of Oric Pharmaceuticals from $15.00 to $12.00 and set an "outperform" rating for the company in a report on Tuesday, May 6th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average price target of $19.17.

About Oric Pharmaceuticals

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.